Results 191 to 200 of about 27,641 (272)

A Stakeholder map

open access: yes
A report that gives an overview of existing and potential stakeholders by sector (e.g. government policy, business, NGO’s, science and the public, particularly Arctic residents and indigenous people) that are likely to be end-users or influencers of polar research.
openaire   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

How to do (or not to do)… asset mapping in community health. [PDF]

open access: yesHealth Policy Plan
Chen X   +9 more
europepmc   +1 more source

Evidence to support integrating feedback best practice for computer‐based assessment in pharmacology education

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Feedback is the most powerful driver of learning, but it can afford variable effects depending on the method used. The design of feedback for computer‐based assessment—now increasingly prevalent in higher education—remains relatively underexplored, particularly for pharmacology education.
Claire Y. Hepburn
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner   +5 more
wiley   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić   +4 more
wiley   +1 more source

Implementation mapping to develop strategies for skin-to-skin care in the pediatric cardiac intensive care unit: planning for a hybrid trial. [PDF]

open access: yesFront Pediatr
Bettencourt A   +7 more
europepmc   +1 more source

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract This review focuses on the development of radiopharmaceutical imaging agents and radioligand therapeutics for paediatric use. Nuclear medicine plays an important role in the diagnosis and treatment of various childhood conditions, including cancers, infections and brain disorders.
Justin L. Hay   +5 more
wiley   +1 more source

Stakeholder priorities and conceptualization of One Health: Insights from fuzzy cognitive mapping and grounded theory. [PDF]

open access: yesPLoS One
Griffith EF   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy